Omni Bio Pharmaceutical’s recombinant AAT-Fc development program is targeted for advancement into clinical trials in 2015/2016
Dec 9, 2014
Omni Bio Announces Encouraging Clinical Data for Use of Alpha-1 Antitrypsin (AAT) in Steroid-Resistant Graft Versus Host Disease
Nov 19, 2014
Omni Bio Announces Presentation of Phase 1/2 Clinical Data for AAT at American Heart Association Scientific Sessions
Read All News
Omni Bio is conducting research on a series of novel and highly competitive recombinant forms of AAT.
Omni Bio Pharmaceutical, Inc.181 W. Boardwalk, Suite 202Fort Collins, CO 80525(970) 237-5178 (Corporate & Investor Inquiries)
Copyright 2014 Omni Bio Pharmaceutical, Inc.